Pyridine derivatives

Details for Australian Patent Application No. 2005266090 (hide)

Owner Pfizer Inc.

Inventors Lane, Charlotte Alice Louise; Rawson, David James; Maw, Graham Nigel; Thompson, Lisa Rosemary

Agent Spruson & Ferguson

Pub. Number AU-A-2005266090

PCT Pub. Number WO2006/011050

Priority 60/646,077 21.01.05 US; 0416524.7 23.07.04 GB

Filing date 12 July 2005

Wipo publication date 2 February 2006

International Classifications

C07D 213/81 (2006.01) Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members

A61K 31/44 (2006.01) - Non-condensed pyridines

A61K 31/4439 (2006.01)

A61P 29/00 (2006.01) Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

Event Publications

1 February 2007 PCT application entered the National Phase

  PCT publication WO2006/011050 Priority application(s): WO2006/011050

7 January 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005266095-Attachment of components to composite materials

2005266088-Compositions for treatment of inflammation and pain using a combination of a COX-2 selective inhibitor and a LTB4 receptor antagonist